PortalPublikationenBRAF V600E Mutation in First-line Metastatic Colorectal Canc...

BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database

Standard

BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database. / Cohen, Romain; Liu, Heshan; Fiskum, Jack; Adams, Richard; Chibaudel, Benoist; Maughan, Timothy S; Van Cutsem, Eric; Venook, Alan; Douillard, Jean-Yves; Heinemann, Volker; Punt, Cornelis J A; Falcone, Alfredo; Bokemeyer, Carsten; Kaplan, Richard; Lenz, Heinz-Josef; Koopman, Miriam; Yoshino, Takayuki; Zalcberg, John; Grothey, Alex; de Gramont, Aimery; Shi, Qian; André, Thierry.

in: JNCI-J NATL CANCER I, Jahrgang 113, Nr. 10, 01.10.2021, S. 1386-1395.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Cohen, R, Liu, H, Fiskum, J, Adams, R, Chibaudel, B, Maughan, TS, Van Cutsem, E, Venook, A, Douillard, J-Y, Heinemann, V, Punt, CJA, Falcone, A, Bokemeyer, C, Kaplan, R, Lenz, H-J, Koopman, M, Yoshino, T, Zalcberg, J, Grothey, A, de Gramont, A, Shi, Q & André, T 2021, 'BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database', JNCI-J NATL CANCER I, Jg. 113, Nr. 10, S. 1386-1395. https://doi.org/10.1093/jnci/djab042

APA

Cohen, R., Liu, H., Fiskum, J., Adams, R., Chibaudel, B., Maughan, T. S., Van Cutsem, E., Venook, A., Douillard, J-Y., Heinemann, V., Punt, C. J. A., Falcone, A., Bokemeyer, C., Kaplan, R., Lenz, H-J., Koopman, M., Yoshino, T., Zalcberg, J., Grothey, A., ... André, T. (2021). BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database. JNCI-J NATL CANCER I, 113(10), 1386-1395. https://doi.org/10.1093/jnci/djab042

Vancouver

Cohen R, Liu H, Fiskum J, Adams R, Chibaudel B, Maughan TS et al. BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database. JNCI-J NATL CANCER I. 2021 Okt 1;113(10):1386-1395. https://doi.org/10.1093/jnci/djab042

Bibtex

@article{368cebb028894c16af8dd8f429257f33,
title = "BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database",
abstract = "BACKGROUND: First-line therapeutic strategies for patients with BRAFV600E-mutated (BRAFmt) metastatic colorectal cancer (mCRC) mainly rely on subgroup analyses from randomized controlled trials (RCTs). We aimed to assess the prognostic and predictive impact of BRAFmt on the efficacy of targeted therapies with first-line chemotherapy.METHODS: Individual patient data from first-line RCTs with BRAF and KRAS status data in the ARCAD database were pooled. Progression-free survival and overall survival (OS) were assessed using Kaplan-Meier and Cox models. Outcomes were compared between treatment groups that were concurrently randomly assigned whenever possible.RESULTS: A total of 6391 patients from 10 RCTs were included: 573 BRAFmt (9.0%), 2059 KRASmt (32.2%), and 3759 double wild type (58.8%). BRAFmt mCRC patients experienced statistically significantly poorer OS than those with KRASmt (adjusted hazard ratio [HRadj] = 1.46, 95% confidence interval [CI] = 1.30 to 1.64) and patients with double wild-type tumors (HRadj = 2.14, 95% CI = 1.94 to 2.36). Anti-EGFR agents did not improve progression-free survival or OS of BRAFmt mCRC patients, based on 4 RCTs testing chemotherapy with or without anti-epidermal growth factor receptor (anti-EGFR) (HRadj = 0.96, 95% CI = 0.71 to 1.30; and HRadj = 0.85, 95% CI = 0.66 to 1.14, respectively).CONCLUSIONS: Our data suggest that the addition of anti-EGFR agents to chemotherapy is ineffective as first-line treatment for BRAFmt mCRC patients.",
author = "Romain Cohen and Heshan Liu and Jack Fiskum and Richard Adams and Benoist Chibaudel and Maughan, {Timothy S} and {Van Cutsem}, Eric and Alan Venook and Jean-Yves Douillard and Volker Heinemann and Punt, {Cornelis J A} and Alfredo Falcone and Carsten Bokemeyer and Richard Kaplan and Heinz-Josef Lenz and Miriam Koopman and Takayuki Yoshino and John Zalcberg and Alex Grothey and {de Gramont}, Aimery and Qian Shi and Thierry Andr{\'e}",
note = "{\textcopyright} The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.",
year = "2021",
month = oct,
day = "1",
doi = "10.1093/jnci/djab042",
language = "English",
volume = "113",
pages = "1386--1395",
journal = "JNCI-J NATL CANCER I",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "10",

}

RIS

TY - JOUR

T1 - BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database

AU - Cohen, Romain

AU - Liu, Heshan

AU - Fiskum, Jack

AU - Adams, Richard

AU - Chibaudel, Benoist

AU - Maughan, Timothy S

AU - Van Cutsem, Eric

AU - Venook, Alan

AU - Douillard, Jean-Yves

AU - Heinemann, Volker

AU - Punt, Cornelis J A

AU - Falcone, Alfredo

AU - Bokemeyer, Carsten

AU - Kaplan, Richard

AU - Lenz, Heinz-Josef

AU - Koopman, Miriam

AU - Yoshino, Takayuki

AU - Zalcberg, John

AU - Grothey, Alex

AU - de Gramont, Aimery

AU - Shi, Qian

AU - André, Thierry

N1 - © The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

PY - 2021/10/1

Y1 - 2021/10/1

N2 - BACKGROUND: First-line therapeutic strategies for patients with BRAFV600E-mutated (BRAFmt) metastatic colorectal cancer (mCRC) mainly rely on subgroup analyses from randomized controlled trials (RCTs). We aimed to assess the prognostic and predictive impact of BRAFmt on the efficacy of targeted therapies with first-line chemotherapy.METHODS: Individual patient data from first-line RCTs with BRAF and KRAS status data in the ARCAD database were pooled. Progression-free survival and overall survival (OS) were assessed using Kaplan-Meier and Cox models. Outcomes were compared between treatment groups that were concurrently randomly assigned whenever possible.RESULTS: A total of 6391 patients from 10 RCTs were included: 573 BRAFmt (9.0%), 2059 KRASmt (32.2%), and 3759 double wild type (58.8%). BRAFmt mCRC patients experienced statistically significantly poorer OS than those with KRASmt (adjusted hazard ratio [HRadj] = 1.46, 95% confidence interval [CI] = 1.30 to 1.64) and patients with double wild-type tumors (HRadj = 2.14, 95% CI = 1.94 to 2.36). Anti-EGFR agents did not improve progression-free survival or OS of BRAFmt mCRC patients, based on 4 RCTs testing chemotherapy with or without anti-epidermal growth factor receptor (anti-EGFR) (HRadj = 0.96, 95% CI = 0.71 to 1.30; and HRadj = 0.85, 95% CI = 0.66 to 1.14, respectively).CONCLUSIONS: Our data suggest that the addition of anti-EGFR agents to chemotherapy is ineffective as first-line treatment for BRAFmt mCRC patients.

AB - BACKGROUND: First-line therapeutic strategies for patients with BRAFV600E-mutated (BRAFmt) metastatic colorectal cancer (mCRC) mainly rely on subgroup analyses from randomized controlled trials (RCTs). We aimed to assess the prognostic and predictive impact of BRAFmt on the efficacy of targeted therapies with first-line chemotherapy.METHODS: Individual patient data from first-line RCTs with BRAF and KRAS status data in the ARCAD database were pooled. Progression-free survival and overall survival (OS) were assessed using Kaplan-Meier and Cox models. Outcomes were compared between treatment groups that were concurrently randomly assigned whenever possible.RESULTS: A total of 6391 patients from 10 RCTs were included: 573 BRAFmt (9.0%), 2059 KRASmt (32.2%), and 3759 double wild type (58.8%). BRAFmt mCRC patients experienced statistically significantly poorer OS than those with KRASmt (adjusted hazard ratio [HRadj] = 1.46, 95% confidence interval [CI] = 1.30 to 1.64) and patients with double wild-type tumors (HRadj = 2.14, 95% CI = 1.94 to 2.36). Anti-EGFR agents did not improve progression-free survival or OS of BRAFmt mCRC patients, based on 4 RCTs testing chemotherapy with or without anti-epidermal growth factor receptor (anti-EGFR) (HRadj = 0.96, 95% CI = 0.71 to 1.30; and HRadj = 0.85, 95% CI = 0.66 to 1.14, respectively).CONCLUSIONS: Our data suggest that the addition of anti-EGFR agents to chemotherapy is ineffective as first-line treatment for BRAFmt mCRC patients.

U2 - 10.1093/jnci/djab042

DO - 10.1093/jnci/djab042

M3 - SCORING: Journal article

C2 - 33734401

VL - 113

SP - 1386

EP - 1395

JO - JNCI-J NATL CANCER I

JF - JNCI-J NATL CANCER I

SN - 0027-8874

IS - 10

ER -